Fresenius SE & Co. KGaA stock gains traction as short interest plunges 66.5% amid 2025 Annual Report release

Fresenius SE & Co. KGaA (ISIN: DE0005785604) sees sharply reduced short interest on OTCMKTS:FSNUY, dropping 66.5% to just 21,913 shares as of March 13, signaling bullish sentiment. The company released its 2025 Annual Report highlighting strong performance, while US investors eye stable growth in healthcare segments like clinical nutrition via Fresubin products.

Fresenius SE & Co. KGaA stock is drawing fresh attention from investors after a dramatic 66.5% plunge in short interest on its US OTC listing. This shift coincides with the release of the company's 2025 Annual Report, which underscores a year of robust performance and strategic progress under its REJUVENATE initiative. For US investors, the combination points to improving market confidence in this global healthcare giant's resilience amid sector headwinds.

As of: 26.03.2026

Dr. Elena Hartmann, Senior Healthcare Equity Analyst: Fresenius SE & Co. KGaA exemplifies steady execution in dialysis and infusion markets, where demographic tailwinds meet operational discipline for long-term US portfolio stability.

Sharp Drop in Short Interest Signals Bullish Turn

Short interest in Fresenius SE & Co. KGaA's OTC shares (OTCMKTS:FSNUY) fell 66.5% to 21,913 shares as of March 13, from 65,445 shares on February 26. This leaves a days-to-cover ratio of just 0.1 days based on average volume of 220,277 shares, effectively representing near-zero short exposure. Wall Street analysts maintain a positive stance, with three Buy ratings including overweight from Morgan Stanley and buy from Citigroup.

The FSNUY shares traded up 0.3% to $12.93 on OTCMKTS during recent sessions, with a market cap around $29.1 billion. This low short interest reflects growing optimism, particularly as the company navigates healthcare reimbursement pressures and supply chain dynamics common in Europe-based multinationals accessible to US investors.

For US portfolios, FSNUY offers a low-beta (0.75) entry into global healthcare, contrasting with higher-volatility domestic plays. The stock's 50-day moving average stands at $14.33 and 200-day at $14.42 on OTCMKTS, suggesting potential stabilization after recent dips.

2025 Annual Report Highlights Strong Execution

Fresenius released its 2025 Annual Report on March 25, 2026, confirming 2025 as another strong year with the REJUVENATE program driving efficiency gains. Announced in late February, the report details progress across dialysis products, hospital care, and infusion therapies, core to the group's four business segments.

Headquartered in Bad Homburg, Germany, Fresenius SE & Co. KGaA operates globally, providing dialysis, hospital, and outpatient medical care services. The company's scale supports R&D investment, vital for US investors tracking medtech innovation pipelines.

Last quarter, Fresenius reported $0.28 EPS on $6.94 billion revenue, with net margin at 5.71% and ROE of 10.38%. Analysts project $0.79 EPS for the full year, underpinned by steady demand in chronic care areas.

US Investor Appeal Through OTC Access and Stability

US investors access Fresenius via OTCMKTS:FSNUY, which hit a 12-month low of $9.78 and high of $33.93. The ADR structure simplifies exposure to a €29 billion market cap firm with quick ratio of 0.99 and debt-to-equity of 0.49, indicating solid liquidity.

Fresenius Kabi, contributing 39% of revenues, focuses on clinical nutrition like Fresubin drinks, key in the US $15 billion market. These high-calorie supplements aid malnutrition risk in aging populations and chronic disease patients, reducing hospital readmissions by 15-20% in compliant cases.

With US partnerships bolstering supply chains, Fresenius offers demographic-driven growth. Analysts see 5-7% CAGR in nutrition, supported by 6% R&D spend and 15-year dividend growth streak at 2.6% yield.

Segment Deep Dive: Clinical Nutrition and Beyond

Fresubin from Fresenius Kabi meets pharmacopeia standards with manufacturing upgrades ensuring reliable US hospital supply. Sustainability efforts cut plastic by 20% and earn carbon certifications, aiding tender wins with eco-focused providers.

Digital tools like nutrition calculators and upcoming AI personalization expand prescriptions via tele-nutrition platforms. Global expansion targets bariatrics, enhancing US adjacency growth.

Peptide therapeutics market, where Fresenius competes alongside Baxter and Pfizer, projects 7.16% CAGR to $70.20 billion by 2031, fueled by cancer and metabolic disorders. Fresenius' infusion and nutrition resilience shines amid this.

Financial Health and Strategic Positioning

Fresenius maintains current ratio of 1.26, supporting capex and R&D. Strategic divestitures refocus on core segments, boosting Kabi agility. ESG ratings emphasize sustainable supply chains, appealing to institutional US funds.

Balance sheet strength funds innovation, with margins expanding from scale. The REJUVENATE program targets efficiency, critical for competing in consolidated healthcare markets.

Recent quarters show consistent revenue execution, with Q4 2025 EPS beating expectations. Forward guidance aligns with peer growth rates in medtech.

Risks and Open Questions for Investors

Despite positives, Fresenius faces reimbursement cuts in Europe and US pricing pressures. Debt levels, though manageable, warrant monitoring amid rate environments. Supply chain disruptions remain a sector risk.

OTC liquidity trails primary Xetra listing (FRE.DE), potentially amplifying volatility for US traders. Regulatory scrutiny on infusions could impact Kabi margins.

Macro factors like energy costs affect manufacturing, though Fresenius' diversification mitigates. Investors should track Q1 2026 results for REJUVENATE updates.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.